Abbott Laboratories (ABT)

FDA approval of ABT's dual glucose/ketone CGMs is coming soon; the products are already approved in Europe.

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosisJune 6, 2026 9:00 AM
PR Newswire (US) Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in interventionNearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes. Findings from multiple Abbott studies shared at the American Diabetes Association's (ADA) June 2026 86th Scientific Sessions show sharp increases in DKA-related hospitalizations across all age groups nationwide. The data reinforces that while diabetes technology has advanced significantly, there are opportunities to better detect rising ketones before DKA develops.Diabetic Ketoacidosis: Often Misunderstood and Difficult to Recognize DKA develops in people with diabetes when the body does not have enough insulin and begins breaking down fat for energy, causing ketones to rise to dangerous levels in the blood.2 While traditionally associated with Type 1 diabetes, DKA is increasingly affecting people with Type 2 diabetes. The American Diabetes Association notes that high ketone levels can escalate to DKA within hours and, if left untreated, can lead to coma or death.2 Many people living with diabetes aren't familiar with DKA or its symptoms, despite clinical guidance recommending ketone testing during periods of elevated glucose, making it a challenge to detect early.New DKA Data from Abbott Presented at ADA's Scientific SessionsAt the ADA's Scientific Sessions, Abbott presented findings from multiple studies analyzing hospitalization, admission diagnosis and insurance claims data to better understand how DKA may be challenging to identify, its rising impact among young people, and a growing prevalence in adults with Type 2 diabetes.DKA may be hard to identify early at hospital admissions: A study of over 100,000 people across the U.S. found that DKA can be difficult to recognize when a person first arrives at the hospital, as early symptoms – such as nausea, fatigue, or stomach pain – overlap with many common illnesses.3 A confirmed diagnosis of DKA depends on blood tests that measure blood sugar, blood pH and/or bicarbonate levels, and ketones, which may not be immediately available at admission.2 These delays highlight the need for approaches to recognize DKA earlier to provide timely care.Better awareness of DKA may help curb hospitalizations: A second study of over 200,000 people showed that between 2017-2024, DKA hospitalization rates among people with Type 1 diabetes increased approximately 24%, rising from 50 to 62 cases per 1,000 individuals. The increase was more pronounced in children than adults.4 Most DKA events led to hospitalization for both children and adults, while severe hypoglycemia rates stayed low and stable, likely due to greater recognition of hypoglycemia and less awareness of DKA risk.4Reducing DKA hospitalizations may improve health outcomes across all ages: One analysis of close to 40,000 pediatric hospitalizations showed DKA now drives nearly 60% of all diabetes-related hospitalizations among youth with Type 1 or Type 2 diabetes.1 Most U.S. hospitalizations among children with diabetes are related to DKA, with the majority requiring inpatient care lasting up to one week and costing up to $38,000 per stay.1 Findings from a separate study with data from millions of people indicate DKA is likely underreported in adults with Type 2 diabetes, and when diagnosed after admission as a secondary condition, is associated with longer hospital stays, higher costs, and increased rates of death.5"These findings from Abbott show that diabetic ketoacidosis remains a growing challenge to identify, as DKA can develop quickly and mimic common illnesses," said Kurt Midyett, M.D., pediatric endocrinologist at Saint Luke's Endocrinology Specialists in Kansas City, Mo. "When early symptoms are misattributed, delays in diagnosis are common and often result in lengthy and costly hospitalization. This data underscores the importance of addressing gaps in recognition to help detect rising ketones before DKA develops."The Role of Ketone Monitoring in Diabetes CareContinuous glucose monitors (CGMs) play an essential role in helping people manage their diabetes by providing real-time glucose insights. However, they do not currently measure ketones and DKA can still develop even when glucose levels appear stable.6 Insights from adults living with Type 1 diabetes show that while some people understand the importance of monitoring ketones, testing is often underused. Rising ketones can progress to DKA within hours, so earlier visibility has the potential to prompt action sooner and reduce risk.6"These new data make clear that preventing diabetic ketoacidosis starts with recognizing risk earlier," said Mahmood Kazemi, M.D., chief medical officer for Abbott's diabetes care business. "DKA remains one of the most preventable emergencies in diabetes care, yet too many people still miss early warning signs when ketones levels begin to rise. These findings underscore the need for better ways to recognize risk sooner and help reduce avoidable hospitalizations."As an alternative to existing ketone monitoring options, Abbott has developed dual glucose-ketone sensing technology, which combines continuous glucose and ketone monitoring in a single sensor designed to support both daily diabetes management and help to detect rising ketone levels for people living with diabetes. Abbott announced CE Mark for the systems, called Libre Duo and Libre Duo 10 Day, in May 2026. The company has also filed a regulatory submission with the U.S. Food & Drug Administration (FDA). Libre Duo and Libre Duo 10 Day systems are not yet cleared by the FDA or available for sale in the United States.Frequently Asked QuestionsWhat is diabetic ketoacidosis?Diabetic ketoacidosis (DKA) occurs when the body doesn't have enough insulin. To get energy, the body starts breaking down fat, which releases acids called ketones into the blood.  People in DKA can experience severe dehydration, dangerous changes to potassium and other electrolytes, and coma.  Without prompt treatment, DKA can lead to coma or death.Can people use urine and blood ketone monitors to test ketones? Urine and blood ketone monitors are available, but they only offer a snapshot in time and depend on individuals or caregivers recognizing symptoms and deciding to test. Many do not check ketones regularly or lack testing supplies, which can delay action. In a study published in the British Medical Journal Open Diabetes Research & Care, 64% of participants do not test for ketones at all, which can lead to rising ketones that may go unnoticed until a medical emergency develops.7Can a continuous glucose monitor (CGM) provide information that helps prevent diabetic ketoacidosis? A CGM, like the FreeStyle Libre 3 Plus sensor, can play an important role in diabetes management, but they are not designed to measure ketones. Because rising ketones are a key driver of diabetic ketoacidosis, relying on glucose data alone may not always provide an early warning before diabetic ketoacidosis (DKA) develops. Abbott has developed a dual glucose-ketone sensing technology in the U.S. that is pending FDA clearance.About Libre:
Abbott continues to pioneer groundbreaking technology to support people living with diabetes. The company revolutionized diabetes care more than 10 years ago with its world-leading Libre continuous glucose monitoring portfolio8, which today is used by more than 8 million people across over 60 countries. People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals. There is full or partial reimbursement for Libre systems in more than 40 countries.8About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.Important Safety Information: FreeStyle Libre 3 system is for prescription only, for Important Safety Information, please visit https://www.freestyle.abbott/us-en/safety-information.html.1 Sherr et al. Burden Of Diabetic Ketoacidosis Among Youth With Diabetes: A Hospital Claims Analysis.
2 American Diabetes Association. "Planning for Sick Days." Accessed February 6, 2026. https://diabetes.org/getting-sick-with-diabetes/sick-days. 
3 Miller et al. Characterizing the Clinical Presentation of Diabetic Ketoacidosis Hospitalizations in People with Diabetes using Admitting Diagnoses. 
4 Trends in the Prevalence of Diabetic Ketoacidosis and Severe Hypoglycemia in Type 1 Diabetes. 
5 Galindo et al. Mortality And Costs of Diabetic Ketoacidosis Hospitalizations in People with Type 2 Diabetes: Differences Between Primary Vs. Secondary Diagnosis.
6 Dhatariya, et al. Lancet Diabetes & Endocrinology (2025): https://pubmed.ncbi.nlm.nih.gov/41381175/
7 Hepprich, M., Roser, P., Stiebitz, S., Felix, B., Schultes, B., Schmitz, D., Rutishauser, J., Schubert, S., Aberle, J., & Rudofsky, G. (2023). Awareness and knowledge of diabetic ketoacidosis in people with type 1 diabetes: a cross-sectional, multicenter survey. BMJ open diabetes research & care, 11(6), e003662. https://doi.org/10.1136/bmjdrc-2023-003662 
8 Data on File, Abbott Diabetes Care. Data based on the number of patients assigned to each manufacturer. View original content:https://www.prnewswire.com/news-releases/new-abbott-data-show-many-people-with-diabetes-may-not-recognize-symptoms-of-diabetic-ketoacidosis-302793024.htmlSOURCE Abbott Original: New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetesMay 28, 2026 3:00 AM
PR Newswire (US) First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetesIntegrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providersDesigned for compatibility with leading automated insulin delivery (AID) systemsABBOTT PARK, Ill., May 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose–ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose and ketone levels every minute, providing real-time visibility into both glucose levels needed for daily diabetes management as well as rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency. This marks the first time people with diabetes will be able to monitor ketones without traditional blood or urine tests. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Why monitoring ketones matters for people with diabetes
In people with diabetes, DKA develops when the body does not have enough insulin and begins breaking down fat for energy, causing ketones to rise to dangerous levels in the blood.1 According to the American Diabetes Association, elevated ketones can escalate to DKA within hours and, if left untreated, can lead to coma or death.1 Yet, despite clinical guidance recommending ketone testing during illness or periods of elevated glucose, early detection remains a persistent challenge.How Libre Duo systems work
Libre Duo systems continuously monitor both glucose and ketone levels, reducing reliance on blood or urine tests that capture only a single moment in time. The sensors are designed to help people with diabetes monitor glucose levels – the standard of care for daily diabetes management – while also alerting people to rising ketones so they can take action sooner and potentially avoid a serious DKA emergency.This CE Mark covers two Libre Duo systems. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Clinical data indicate that a 10-day sensor can help active youth complete the full wear period. Both sensors deliver consistent, strong accuracy.Libre Duo systems will integrate with Abbott's Libre digital health ecosystem, enabling users to share glucose and ketone data with caregivers and healthcare providers. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors."Abbott has a long-established pattern of setting the pace in health tech innovation," said Chris Scoggins, executive vice president of Abbott's diabetes care business. "People living with diabetes routinely tell us that the risk of serious complications is a constant part of everyday life. Our Libre Duo systems offer people with diabetes, families and healthcare providers clearer, earlier information about what's happening inside their body, allowing them to act sooner when safety matters most."Libre Duo systems align with recommendations outlined in a recent international expert consensus paper from Breakthrough T1D, a global organisation focused on Type 1 diabetes research and advocacy, which describes the safe and effective use of continuous ketone monitoring as part of diabetes management. 2Hilary Nathan, director of policy at Breakthrough T1D in the UK, said: "Type 1 diabetes is as individual as the people living with it, and there is no one-size-fits-all approach to managing it. That is why access to a range of technologies and genuine choice is so essential. It is tremendous to see innovation moving forward with tools like dual ketone and glucose monitoring, giving people more options to understand and manage their condition in real time. At Breakthrough T1D, we welcome advances like this, which reflect the realities of daily life with Type 1 diabetes."A growing gap in diabetes care
DKA can develop quickly and is often difficult to detect early. Because ketones are not routinely monitored, warning signs are frequently missed, contributing to delayed intervention and rising rates of DKA. Recent data illustrate the scale of these challenges:Glucose and ketones don't always rise together: Ketones can rise independently of glucose levels and, in some cases, even when glucose appears in range, which can delay detection of diabetic ketoacidosis (DKA) risk.2DKA rates are rising: According to research published in the peer-reviewed journal, Diabetes Care, hospital admissions for DKA have increased approximately 55% over the past decade, and the U.S. Centers for Disease Control and Prevention (CDC) lists DKA as a leading cause of death among children and adults under age 58 with Type 1 diabetes.3 A recent analysis of nearly 660,000 people in the United Kingdom, conducted by leading diabetes researchers and presented at the 2026 Conference for Advanced Technologies & Treatments for Diabetes (ATTD), found that DKA rates are increasing among people with both Type 1 and Type 2 diabetes, with a high risk of recurrence. Over the 23-year study period, DKA incidence in adults with Type 1 diabetes more than tripled, while incidence among people with Type 2 diabetes increased sixfold.4DKA leads to more hospitalisations than hypoglycaemia: According to the CDC, DKA accounts for approximately four times more hospitalisations than hypoglycaemia, making it the dominant driver of acute diabetes-related healthcare utilisation in the U.S.5Symptoms are often missed: Early signs of rising ketones, such as nausea, fatigue or flu–like illness, are frequently mistaken for common infections, delaying recognition and treatment.2,6,7Ketone monitoring remains limited: In a survey of nearly 3,000 people with Type 1 diabetes published in the peer-reviewed journal, Diabetes Care, only 18% reported having a blood ketone meter at home, while nearly one–third reported having no ketone testing supplies – blood meters or urine strips – at all.8Frequently Asked QuestionsWhat is Libre Duo?
Libre Duo systems are two-in-one biowearables that provide real-time visibility into both glucose levels and ketones. Early detection of rising ketones may help people avoid a serious diabetic ketoacidosis (DKA) emergency.1Who should use Libre Duo?
Libre Duo systems are designed for people with diabetes with higher risk for DKA, including people with Type 1 or Type 2 diabetes who use insulin or other glucose-lowering medications, such as sodium-glucose cotransporter 2 inhibitors, also known as SGLT2sDo people with diabetes need a continuous ketone monitor?
Continuous glucose monitors (CGMs) track glucose, but they do not measure ketones. According to the American Diabetes Association, elevated ketones can progress to DKA within hours, making early detection critical. Because ketone levels can rise quickly — sometimes independently of glucose — and symptoms are often mistaken for common illnesses, having visibility into ketone trends may help people better understand when they could be at risk and take action sooner.1,2,4,6About Libre:
Abbott continues to pioneer groundbreaking technology to support people living with diabetes. The company revolutionised diabetes care more than 10 years ago with its world-leading Libre continuous glucose monitoring portfolio, which today is used by more than 8 million people across over 60 countries.9 People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals.About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.






1American Diabetes Association. "Planning for Sick Days." Accessed February 6, 2026. https://diabetes.org/getting-sick-with-diabetes/sick-days.2Dhatariya, et al. Lancet Diabetes & Endocrinology (2025): https://pubmed.ncbi.nlm.nih.gov/41381175/3Umpierrez, et al. Diabetes Care (2024): https://doi.org/10.2337/dci24-0032.4Seidu S. et al. 'Rising burden of diabetic ketoacidosis in the UK: 23-year trends, recurrence, and predictors from linked primary–secondary care data.' Oral presentation, ATTD 2026, Barcelona, Spain, 11-14 March 2026.5Centers for Disease Control. "National Diabetes Statistics Report." Accessed May 4, 2026. National Diabetes Statistics Report - United States Diabetes Surveillance System6Virdi, N. Diabetes Technology & Therapeutics (2023). https://doi.org/10.1089/dia.2023.0149. 7Nguyen, K. T. Journal of Diabetes Science and Technology (2022). https://doi.org/10.1177/19322968211042656.8Albanese-O'Neill et al. Diabetes Care (2017): https://doi.org/10.2337/dc16-2620.9Data on File, Abbott Diabetes Care. Data based on the number of patients assigned to each manufacturer. View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/abbott-secures-ce-mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes-302782706.html Original: Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screeningMay 27, 2026 7:01 AM
PR Newswire (US) Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guidelineAbbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based optionsRecent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payersABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC. Both tests are used at a three-year interval.Cologuard and Cologuard Plus are preferred, U.S. Preventive Services Task Force-recommended noninvasive screening tests designed to detect CRC early – when it is most treatable – and identify precancerous lesions that can be removed during follow-up colonoscopy.1 Cologuard Plus detects 95% of colorectal cancers at 94% specificity age-weighted to the U.S. screening population, which is expected to minimize unnecessary follow-up colonoscopies and maximize confidence in results.2* Both tests are backed by Abbott's well-established patient navigation support and commercial infrastructure to ensure scale, reliability, and seamless patient and provider experiences. Further, both tests are included in colorectal cancer screening quality measures, such as HEDIS and Stars, which support payer and provider quality incentives."Colorectal cancer is highly treatable when caught early – survivable in about 90% of cases – and is even preventable when pre-cancers are found and removed. But still, up to 60 million eligible Americans remain unscreened," said Dr. Xavier Llor, professor of medicine and director, GI and Pancreatic Cancer Prevention Program, Yale School of Medicine.† "Screening tools like Cologuard and Cologuard Plus allow us to offer additional well-performing options to cater to the needs of different patients, increasing the chances at positively impacting incidence and mortality rates from this devastating disease in the United States."Abbott Uniquely Positioned to Expand Screening in Line with ACS Guideline
With the proven performance and broad adoption of Cologuard and Cologuard Plus, alongside Abbott's agreement to commercialize a blood-based test from Freenome, pending FDA approval, Abbott is uniquely positioned across the spectrum of noninvasive CRC screening. Upon approval, Abbott will launch the blood-based test with a seamless ordering experience designed to expand participation among individuals who decline other screening methods. Cologuard tests will continue to serve as preferred first-line screening options to help drive optimal outcomes. Both tests will leverage Abbott's Nexus platform, which helps providers identify patients who are not up to date on CRC screening and improve adherence over time.Proven CRC Screening Impact of Cologuard Enters New Era with Cologuard Plus
Cologuard tests have transformed colorectal cancer screening, driving an estimated 77% of the nationwide increase in CRC screening participation from 2018 to 2021.3 First included in the ACS Colorectal Cancer Screening Guideline in 2014, the tests have been used more than 23 million times.4 Supported by a robust patient navigation program, Cologuard tests have demonstrated strong real-world adherence to initial screening,5 category-leading follow-up colonoscopy rates when needed,6 and high patient satisfaction,4 supporting repeat screening at the guideline-recommended three-year interval.This impact is further reinforced by peer-reviewed modeling studies. One recently published analysis found that a Cologuard-first screening approach could nearly double CRC detection, prevent more cancers through the detection and removal of precancerous lesions, and reduce CRC-related costs while allowing colonoscopy capacity to focus on follow-up and therapeutic procedures.7 A separate modeling study suggests that Cologuard Plus, when used at guideline-recommended intervals, could detect more cancers and precancerous lesions, reduce mortality, and deliver substantially more life-years gained over 10 years than a single screening colonoscopy.8 These outcomes were driven by strong test performance and high adherence to both initial screening and follow-up colonoscopy."The updated ACS guideline reinforces the importance of screening approaches that combine strong clinical performance with the ability to reach more patients," said Paul Limburg, M.D., chief medical officer, screening, Abbott's cancer diagnostics business. "With Cologuard and Cologuard Plus established as preferred first-line screening options, Abbott is well-positioned across both stool- and blood-based approaches to help close persistent screening gaps and improve outcomes in colorectal cancer."ACS is a leading cancer advocacy organization that develops evidence-based guidelines to inform clinicians, policymakers and the public, helping shape cancer prevention, screening, and early detection practices.About the Cologuard and Cologuard Plus tests
Developed in collaboration with Mayo Clinic, the Cologuard and Cologuard Plus tests are first-line, noninvasive colorectal cancer (CRC) screening options for adults aged 45 or older who are at average risk for the disease. The Cologuard test revolutionized CRC screening by detecting specific DNA markers and blood in stool associated with cancer and precancer, allowing patients to complete the collection kit at home without special preparation or time off, and return the kit to the lab for results. It is also the only noninvasive molecular CRC screening test recommended by USPSTF (2021), and both Cologuard and Cologuard Plus are included in HEDIS® quality measures and the ACS guidelines (2026).Building on this success, the FDA-approved Cologuard Plus test features novel biomarkers, improved laboratory processes, and enhanced sample stability. Through high performance, the Cologuard Plus test is designed to reduce the likelihood of false positives, helping to minimize unnecessary follow-up colonoscopies. Further, Cologuard Plus is the only noninvasive test FDA-approved for both cancer and precancer detection. Both tests demonstrate Abbott's commitment to improving CRC screening access and outcomes.Cologuard and Cologuard Plus rely exclusively on molecular data from the patient sample – not subjective patient-reported risk factors – reducing variability, improving accuracy, and enabling faster results.About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.* 94% specificity when age-weighted to the U.S. screening population. Cologuard Plus specificity: 91% overall specificity, including all participants who did not have advanced neoplasia.
† Dr. Xavier Llor previously served as a principal investigator on a study with Exact Sciences, which is now Abbott. He was not compensated for media work.Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer - US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977.Cologuard Plus™ Clinician Brochure. Madison, WI: Exact Sciences Corporation.Ebner DW, Finney Rutten LJ, Miller-Wilson LA, et al. Trends in colorectal cancer screening from the National Health Interview Survey: Analysis of the impact of different modalities on overall screening rates. Cancer Prev Res (Phila). 2024; 17(6):275-280.Data on file. Exact Sciences Corporation; Madison, WI. Cologuard Tests Completed. [CL-000581]. 2026.Le QA, Greene M, Gohill S, et al. Adherence to multi-target stool DNA testing for colorectal cancer screening in the United States. Int J Colorectal Dis. 2025;40:16.Greene M, Stieber B, LeMaster JW, et al. Closing the loop in colorectal cancer screening: real-world adherence to follow-up colonoscopy after positive mt-sDNA vs FIT/FOBT, stratified by payer type. Curr Med Res Opin. 2025;41(9):1629-1639.Fendrick AM, Kurlander JE, Vahdat V, Estes C, Gohil S, Limburg PJ, Lieberman DA. Optimizing colonoscopy capacity to maximize colorectal cancer outcomes. Gastro Hep Adv. 2026. doi: 10.1016/j.gastha.2026.100930.Dore M, Ebner DW, Vahdat V, Estes C, Ozbay AB, Foster V, Limburg PJ. Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy. J Med Econ. 2026;29(1):986-993. doi:10.1080/13696998.2026.2645491 View original content:https://www.prnewswire.com/news-releases/acs-guideline-reaffirms-abbott-leadership-in-noninvasive-colorectal-cancer-screening-302782400.htmlSOURCE Abbott Original: ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

ABT ASCO lineup:

https://www.prnewswire.com/news-releases/abbott-showcases-expanding-evidence-across-its-cancer-diagnostics-portfolio-at-asco-2026-302779559.html

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026April 25, 2026 12:30 PM
PR Newswire (US)

Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfoliosSix-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib casesNew data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablationTwo new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker systemABBOTT PARK, Ill., April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios to treat heart rhythm disorders.The data include six-month results from the FlexPulse IDE study, which examines treating complex atrial fibrillation (AFib) cases with the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, as well as new clinical evidence for posterior wall ablation with the Volt™ PFA System. Data were also presented for Abbott's ASCEND CSP IDE trial for the company's investigational UltiSynq™ CSP implantable cardioverter-defibrillator (ICD) lead, as well as a first-in-human evaluation of the LEAP2 chronic early feasibility trial for the investigational AVEIR™ CSP leadless pacemaker system.Positive results support TactiFlex Duo Ablation Catheter, Sensor Enabled
New six-month data from the FlexPulse IDE study provide early insights showing positive patient outcomes with Abbott's TactiFlex Duo Ablation Catheter, Sensor Enabled, and confirms the strong safety and efficacy profile seen in the CE Mark study for treating complex AFib cases. The catheter provides physicians with two energy modes to tailor therapy based on a patient's complex disease or anatomy: radiofrequency – which uses heat energy that destroys tissue responsible for erratic heart signals – and PFA, which uses high energy electrical pulses that destroy the cells causing abnormal heart rhythms.The late-breaking six-month data for the 188-patient FlexPulse IDE study show:iThe majority (87%) of patients reported being free from documented arrhythmias.A high safety profile (98.3%) with no major safety events.The majority (93.3%) of patients were treated exclusively with PFA, demonstrating that this energy source alone was successful in treating complex cases.Physicians efficiently treated their patients – 93.9% did not require an additional ablation after the first round of therapy."The Abbott TactiFlex Duo catheter offers the convenience of seamlessly switching treatment between radiofrequency and pulsed field ablation based upon the patient's anatomy and their personalized ablation plan," said Jonathan P. Piccini, M.D., professor of medicine, Duke University Medical Center, who presented the late-breaking data at HRS. "While RF has long been a well-established ablation approach, with this study, we have been able to show that the TactiFlex Duo's point-to-point PFA is an effective approach for a significant number of our patients."The FlexPulse IDE study was designed to secure U.S. Food and Drug Administration (FDA) approval for the TactiFlex Duo. The catheter received CE Mark in Europe earlier this year.Promising first outcomes for Abbott's investigational conduction system pacing devices
Results from two late-breaking clinical trials evaluated Abbott's investigational leadless and traditional pacing/defibrillation CSP technologies designed to deliver left bundle branch pacing (LBBP), an approach intended to more closely replicate the heart's natural electrical activation. Both data presentations were simultaneously published in Heart Rhythm.The ASCEND CSP IDE trial evaluated the investigational high-voltage UltiSynq CSP ICD lead designed to be implanted in the left bundle branch (LBB) area or the right ventricle to deliver both pacing and defibrillation. The three-month data show UltiSynq CSP successfully met the study's pre-specified primary safety and effectiveness endpoints. Key findings included:iiA high safety profile (97.5%) with no lead-related major safety events reported.A high success rate (99%) meeting left bundle branch area pacing (LBBAP) criteria which can be compared to results from previously reported trial(s). An 86% success rate was met using the more stringent LBBP or likely LBBP criteria. An average of fewer than one (0.9) repositioning attempt per patient was also achieved.100% defibrillation success, with the majority (92.5%) achieving first shock success at 20J. No patients required repositioning of the ICD lead to achieve effective defibrillation.Stable electrical performance at three months, with no inappropriate therapies delivered due to P-wave or T-wave oversensing."Physicians are increasingly using left bundle area pacing for pacemaker patients, because it is associated with improved physiological activation compared with traditional pacing on the right side of the heart," said Rahul N. Doshi, M.D., FHRS, FACC, professor of medicine at Arizona State University. "The data from the ASCEND trial show that an ICD lead designed for physiologic pacing can support restoration of normal heart rhythms when placed in the left bundle branch area. These early results suggest the potential to extend the benefits of physiologic pacing to ICD patients in an efficient manner."Abbott also presented late-breaking results from a first-in-human clinical study evaluating Abbott's investigational AVEIR™ CSP leadless pacemaker system. The one-month data from the 19-patient study found a high implantation success rate along with:iiiDelivery of pacing that closely followed the heart's natural electrical pathways.Reliable electrical performance and functioning at the time of implant and through the first month of follow-up.Consistent communication between devices in a dual-chamber pacemaker setting.New Volt PFA System data confirms freedom from AFib recurrence
Late-breaking six-month data from the Volt CE Mark Extension Cohort trial demonstrated positive outcomes for patients in which the posterior wall of the heart was treated in addition to the standard treatment.New data from the Volt CE Mark Extension Cohort trial show:ivPhysicians cited the device's ease of use and intuitive design as contributors to efficiently treat their patients with fewer therapy applications (4.1 applications per vein and 10.7 per PWI on average) compared to other on-market PFA systems.A high safety profile with no reported patient or procedure-related complications. The Volt PFA System secured FDA approval and CE Mark in Europe last year."Treating abnormal heart rhythms is not a siloed or one-size-fits-all approach, which is why Abbott is creating a holistic cardiovascular portfolio that empowers physicians to care for a wide range of arrhythmias," said Priya Jagasia, divisional vice president of regulatory, clinical, reimbursement and strategic initiatives at Abbott. "The data from these clinical trials serve as a cornerstone for the new innovations we're developing to help people live healthier lives."For U.S. important safety information go to: 
Volt™ PFA System
https://www.cardiovascular.abbott/us/en/ep-clinical-evidence/volt-clinical-evidence.htmlTactiFlex™ Duo Ablation Catheter, Sensor Enabled™, AVEIR™ CSP Leadless Pacemaker System, and UltiSynq™ CSP are approved for investigational use only in the U.S.About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and Youtube._________________________i Piccini, J. (2026, April 25). Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6-Month Results of the FlexPulse IDE Study [Late Breaking Podium]. Heart Rhythm, Chicago, IL, US.iiSchaller, R. (2026, April 25) Safety and efficacy of a novel ICD lead for LBBAP: Results from the ASCEND CSP trial [Late Breaking Presentation]. Heart Rhythm Society 2026, Chicago IL, USA.iii Reddy, V. (2026, April 25) LEAP2: A first-in-human study of a chronically-implanted novel leadless pacemaker for conduction system pacing [Late Breaking Presentation]. Heart Rhythm Society 2026, Chicago IL, USA.iv Sanders, P. (2026, April 24). 6-Month Safety and Effectiveness of Balloon-Based PFA System Left Atrial Posterior Wall Ablation: Results from the Volt CE Mark Extension Cohort [Late Breaking Poster]. Heart Rhythm, Chicago, IL, US.



View original content:https://www.prnewswire.com/news-releases/abbott-showcases-strength-of-its-technologies-to-address-abnormal-heart-rhythms-with-late-breaking-clinical-data-at-heart-rhythm-society-2026-302753567.htmlSOURCE Abbott

Original: Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection TestApril 17, 2026 3:30 PM
PR Newswire (US)

Data show how a multi-biomarker class approach improves early-stage cancer detectionAACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCEDABBOTT PARK, Ill., April 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early detection (MCED) program supporting the commercially available Cancerguard® test. Additionally, the AACR Cancer Prevention Research Award for Outstanding Journal Article will recognize a publication on MCED multiyear outcomes from the DETECT-A study.Multi-biomarker approach enables broader and earlier cancer detection
New data demonstrate how combining methylation (M) and protein (P) biomarkers improves cancer detection across stages, with each biomarker contributing independently to overall performance. Cancerguard is currently the only commercially available MCED test designed with a multi-biomarker class approach, combining methylation and protein signals to improve detection.In a prospectively collected case-control study, nearly half of positive cancer signals were driven by methylation alone (47.1%), with additional detection from protein-only (7.4%) and combined biomarker signals (45.5%), supporting broader detection across cancer types and stages.1 In early-stage disease, many cancer signals were detected by a single biomarker class, demonstrating how each contributes uniquely to overall detection. Notably, none of the 2.6% false-positive results were positive for both biomarkers.1"We designed Cancerguard as the first-of-its-kind multi-biomarker test because no one signal tells the whole story," said Tom Beer, M.D., chief medical officer, multi-cancer early detection, Abbott's cancer diagnostics business. "By combining biomarkers, we can detect cancer earlier, when it matters most."AACR recognizes impactful MCED research with journal award
The AACR Cancer Prevention Research Award for Outstanding Journal Article will be presented to the authors of a 2024 Cancer Prevention Research publication reporting multi-year outcomes from the DETECT-A study, the first large prospective interventional trial of a blood-based MCED test. The study identified nine cancer types, including several without routine screening, and showed that, after a median follow-up of approximately four years, all patients treated for stage I or II cancers remained alive and cancer-free.2,3The award recognizes the significance of these multi-year outcomes data in advancing evidence for the clinical impact of MCED, an area where long-term outcomes data have historically been limited."Long-term follow-up provides critical insight into how multi-cancer early detection can shape the future of cancer screening," said Beer. "With nearly 70 percent of cancers occurring in types without recommended screening, these findings highlight the potential for MCED to increase early detection and improve outcomes."4About the DETECT-A study
The DETECT-A (Detecting cancers Early Through Elective mutation-based blood Collection and Testing) study was the first-ever large, prospective, interventional study to use a blood test to detect multiple types of cancer in a real-world setting. The DETECT-A study enrolled more than 10,000 women with no history of cancer to determine if a blood test in combination with standard-of-care screenings could detect cancers before signs and symptoms appeared. The CancerSEEK test, the MCED test studied in DETECT-A, was the forerunner to the Cancerguard test.About the Cancerguard test 
Cancerguard is a laboratory-developed test (LDT) designed to detect multiple cancers, including the most aggressive cancers, in early stages from a simple blood draw. It integrates two classes of biomarkers to enable broader detection and follows a streamlined, imaging-based diagnostic pathway to help reduce unnecessary follow-up procedures. Developed with high specificity to minimize false positives, the test helps detect a wide range of cancers, including those that lack guideline-recommended screening options.5 The Cancerguard test has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. To learn more, visit cancerguard.com.  About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn,  Facebook,  Instagram,  X and YouTube.Gainullin V et al. AACR Annual Meeting 2026 in San Diego, California. Abstract 1109Buchanan AH, et al. Multiyear clinical outcomes following detection by a blood-based multicancer early detection test. Cancer Prev Res. 2024.N=9 diagnosed with stage I or II cancer. 8 of 8 patients were diagnosed with and treated for stage I or II cancer and achieved remission.Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;e70043. doi:10.3322/caac.70043Cancerguard Clinician Brochure. Exact Sciences Corporation. Madison, WI.



View original content:https://www.prnewswire.com/news-releases/new-data-at-aacr-2026-demonstrate-advancements-in-cancerguard-multi-cancer-early-detection-test-302743788.htmlSOURCE Abbott

Original: New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

Notable catalysts for ABT’s CGM business:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177509453

ABT reports 1Q26 results—adjusts_2026_EPS_guidance_for EXAS acquisition:

https://www.prnewswire.com/news-releases/abbott-reports-first-quarter-2026-results-updates-guidance-to-reflect-acquisition-of-exact-sciences-302744652.html

ABT sold off sharply today due to problems in the nutrition segment (#msg-177508748) for the second consecutive quarter, despite solid performance in medical devices and essentially unchanged 2026 guidance. ABT used to get the benefit of the doubt from investors due to its longstanding track record, but this no longer seems to be the case.

• 1Q26 sales were $11.16B, +4% YoY in constant currency. The EXAS acquisition closed on 3/23/26, so 1Q26 sales did not include a meaningful contribution from EXAS.

• 1Q26 non-GAAP EPS was $1.15, +6% YoY.

• Reiterated 2026 guidance for organic sales growth (which excludes FX, acquisitions, and divestitures) is 6.5-7.5%.

• New 2026 guidance for non-GAAP EPS taking into account EXAS is $5.38-5.58, which includes ($0.20) of dilution from the EXAS acquisition. The prior guidance was $5.55-5.80, so the new guidance is essentially unchanged other than the ($0.20) hit from EXAS. The midpoint of the new EPS range, $5.48, is +6% relative to 2025’s actual $5.15.

See #msg-177508748 for a breakdown of ABT’s 1Q26 results by business segment.

Abbott Shares Slip on Weaker Q2 Outlook Despite In-Line Q1 ResultsApril 16, 2026 10:13 AM
IH Market News
Abbott Laboratories (NYSE:ABT) reported first-quarter earnings on Wednesday that met analyst expectations, while revenue came in slightly ahead of forecasts. However, the stock moved lower after the company issued softer-than-expected guidance for the current quarter.Shares were down 3% in premarket trading as of 07:39 ET.The company posted earnings of $1.15 per share for the first quarter, in line with consensus estimates, while revenue reached $11.16 billion, exceeding expectations of $11 billion. Sales increased 7.8% on a reported basis and 3.7% on a comparable basis.“Our first-quarter results were aligned with our expectations to start the year,” said Robert Ford, chairman and CEO of Abbott. “The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year.”Looking ahead, Abbott expects second-quarter earnings per share to range between $1.25 and $1.31, below the analyst consensus of $1.32.For the full year, the company forecasts EPS between $5.38 and $5.58, compared with a consensus estimate of $5.47. This outlook includes a $0.20 dilution impact related to its acquisition of Exact Sciences, which was completed on March 23.Abbott also anticipates full-year comparable sales growth in the range of 6.5% to 7.5%.Abbott Laboratories stock price

Original: Abbott Shares Slip on Weaker Q2 Outlook Despite In-Line Q1 Results

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesApril 16, 2026 7:30 AM
PR Newswire (US)

First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percentCompleted acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics marketAbbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact SciencesABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE: ABT) announced financial results for the first quarter ended March 31, 2026.
First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.First-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, which excludes specified items and reflects growth of 6 percent.On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's portfolio.Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.In January, Abbott announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter (EV-ICD) system designed to deliver defibrillation therapy to people living with life-threatening heart rhythms.In February, Abbott announced positive early results from the VERITAS study that show clinically meaningful closure rates of the investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).In March, Abbott announced results from the FreeDM2 randomized controlled trial, demonstrating that people with Type 2 diabetes on basal insulin who used FreeStyle Libre® achieved a 0.6% reduction in HbA1c and spent 2.5 more hours per day in the healthy glucose range compared to fingerstick monitoring."Our first-quarter results were aligned with our expectations to start the year," said Robert B. Ford, chairman and chief executive officer, Abbott. "The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year."FIRST-QUARTER BUSINESS OVERVIEWComparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions)Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical DevicesU.S.4,274
844
905
—
2,523International6,890
1,173
1,275
1,426
3,016Total reported11,164
2,017
2,180
1,426
5,539









% Change vs. 1Q25








U.S.2.5
(11.6)
3.8
n/a
7.9International11.3
(1.5)
7.8
13.2
18.0Total reported7.8
(6.0)
6.1
13.2
13.2Total reported excl. foreign exchange impact3.8
(7.7)
2.5
9.0
8.1Comparable sales growth3.7
(7.7)
1.8
9.0
8.5









    U.S.2.5
(11.6)
2.0
n/a
8.7    International4.6
(4.7)
1.6
9.0
8.3Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.  Nutrition
First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions)Total
Pediatric
AdultU.S.844
511
333International1,173
442
731Total reported2,017
953
1,064





% Change vs. 1Q25




U.S.(11.6)
(13.0)
(9.2)International(1.5)
(2.6)
(0.9)Total reported(6.0)
(8.5)
(3.6)Total reported excl. foreign exchange impact(7.7)
(9.7)
(5.9)Comparable sales growth(7.7)
(9.7)
(5.9)





    U.S.(11.6)
(13.0)
(9.2)    International(4.7)
(5.3)
(4.3)Worldwide Nutrition sales decreased 6.0 percent on a reported basis and 7.7 percent on a comparable basis in the first quarter.Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of several new products, are expected to contribute to improved volume growth over the course of the year. Diagnostics*
First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions)Total
Core Laboratory
Cancer Diagnostics
Rapid/Molecular
DiagnosticsU.S.905
347
93
465International1,275
925
3
347Total reported2,180
1,272
96
812







% Change vs. 1Q25






U.S.3.8
4.5
n/a
(13.8)International7.8
9.5
n/a
2.8Total reported6.1
8.1
n/a
(7.4)Total reported excl. foreign exchange impact2.5
3.3
n/a
(9.6)Comparable sales growth1.8
3.3
13.4
(9.6)







    U.S.2.0
4.5
13.2
(13.8)    International1.6
2.8
19.2
(2.7)
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.Worldwide Diagnostics sales increased 6.1 percent on a reported basis and increased 1.8 percent on a comparable basis.Worldwide Core Laboratory Diagnostics results were driven by growth in the U.S., Europe and Latin America. Sales of Core Laboratory diagnostic tests increased on both a year-over-year and sequential basis.Rapid and Molecular Diagnostics results reflect lower demand for respiratory virus tests due to a weaker respiratory virus season compared to the prior year.Results in Cancer Diagnostics reflect Abbott's acquisition of Exact Sciences, which closed on March 23, 2026. Growth in Cancer Diagnostics was driven by double-digit growth of Cologuard® and sales of Cancerguard®, a multi-cancer screening test that launched last year. Established Pharmaceuticals
First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions)Total
Key Emerging
Markets
OtherU.S.—
—
—International1,426
1,089
337Total reported1,426
1,089
337





% Change vs. 1Q25




U.S.n/a
n/a
n/aInternational13.2
12.9
14.1Total reported13.2
12.9
14.1Total reported excl. foreign exchange impact9.0
9.4
7.9Comparable sales growth9.0
9.4
7.9





    U.S.n/a
n/a
n/a    International9.0
9.4
7.9Established Pharmaceuticals sales increased 13.2 percent on a reported basis and 9.0 percent on a comparable basis in the first quarter.Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 12.9 percent on a reported basis and 9.4 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions. Medical Devices
First Quarter 2026 Results (1Q26)
Sales 1Q26 ($ in millions)Total
Rhythm
Management
Electro-physiology*
Heart
Failure
Vascular
Structural
Heart*
Neuro-
modulation
Diabetes
CareU.S.2,523
339
378
292
291
224
177
822International3,016
345
410
97
486
354
66
1,258Total reported5,539
684
788
389
777
578
243
2,080















% Change vs. 1Q25














U.S.7.9
11.5
13.7
11.4
8.6
(9.5)
0.7
9.8International18.0
22.9
19.6
25.2
10.0
25.2
27.2
16.6Total reported13.2
17.0
16.7
14.6
9.5
9.0
6.8
13.8Total reported excl. foreign exchange impact8.1
12.5
12.5
12.2
4.9
3.6
4.1
7.4Comparable sales growth8.5
12.5
12.5
12.2
4.9
6.8
4.1
7.4















    U.S.8.7
11.5
13.7
11.4
8.6
(3.6)
0.7
9.8    International8.3
13.5
11.2
14.9
2.7
15.0
15.5
5.7
*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on Jan. 1, 2026. As a result, $46 million of sales in the first quarter of 2025 were moved from Structural Heart to Electrophysiology.
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.Worldwide Medical Devices sales increased 13.2 percent on a reported basis and 8.5 percent on a comparable basis in the first quarter.Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure and Rhythm Management.In Diabetes Care, sales of continuous glucose monitors grew 14.2 percent on a reported basis and 7.6 percent on a comparable basis.Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.Abbott projects second-quarter 2026 adjusted diluted earnings per share of $1.25 to $1.31.Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.Abbott Declares 409th Consecutive Quarterly Dividend
On Feb. 20, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.Abbott will live-webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking StatementsSome statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott's Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million. Abbott Laboratories and SubsidiariesCondensed Consolidated Statement of EarningsFirst Quarter Ended March 31, 2026 and 2025(in millions, except per share data)(unaudited)


1Q26
1Q25
% Change
Net Sales$11,164
$10,358
7.8







Cost of products sold, excluding amortization expense4,890
4,468
9.5
Amortization of intangible assets422
420
0.3
Research and development767
716
7.2
Selling, general, and administrative3,740
3,061
22.2
Total Operating Cost and Expenses9,819
8,665
13.3







Operating Earnings1,345
1,693
(20.6)







Interest expense, net68
49
37.4
Net foreign exchange (gain) loss(13)
(7)
n/m
Other (income) expense, net(159)
(127)
24.8
Earnings before taxes1,449
1,778
(18.5)
Taxes on Earnings372
453
(18.0)1)






Net Earnings$1,077
$1,325
(18.7)







Net Earnings excluding Specified Items, as described below$2,022
$1,919
5.42)






Diluted Earnings per Common Share$0.61
$0.76
n/m







Diluted Earnings per Common Share, excluding Specified Items, as described below$1.15
$1.09
5.52)






Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options1,747
1,747



NOTES:See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.n/m = Percent change is not meaningful.See footnotes on the following section.

1)2026 Taxes on Earnings includes the recognition of approximately $50 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.


2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $945 million, or $0.54 per share, for intangible amortization, charges related to restructuring, acquisitions, and other net expenses.


2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax benefits of $594 million, or $0.33 per share, for intangible amortization, charges related to investment impairments, restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses. Abbott Laboratories and SubsidiariesNon-GAAP Reconciliation of Financial InformationFirst Quarter Ended March 31, 2026 and 2025(in millions, except per share data)(unaudited)

1Q26
As
Reported
(GAAP)
Specified
Items
As Adjusted





Intangible Amortization$      422
$     (422)
$         —Gross Margin5,852
432
6,284R&D767
(24)
743SG&A3,740
(473)
3,267Other (income) expense, net(159)
(7)
(166)Earnings before taxes1,449
936
2,385Taxes on Earnings372
(9)
363Net Earnings1,077
945
2,022Diluted Earnings per Share$      0.61
$      0.54
$       1.15Specified items reflect intangible amortization expense of $422 million and other net expenses of $514 million associated with restructuring actions, acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
1Q25
As
Reported
(GAAP)
Specified
Items
As Adjusted





Intangible Amortization$      420
$     (420)
$         —Gross Margin5,470
448
5,918R&D716
(27)
689SG&A3,061
(10)
3,051Other (income) expense, net(127)
(35)
(162)Earnings before taxes1,778
520
2,298Taxes on Earnings453
(74)
379Net Earnings1,325
594
1,919Diluted Earnings per Share$      0.76
$      0.33
$      1.09Specified items reflect intangible amortization expense of $420 million and other net expenses of $100 million associated with restructuring actions, acquisitions, investment impairments and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.A reconciliation of the first-quarter tax rates for 2026 and 2025 is shown below: 
1Q26
($ in millions)Pre-TaxIncome
Taxes onEarnings
TaxRate
As reported (GAAP)$    1,449
$       372
25.6 %1)Specified items936
(9)


Excluding specified items$    2,385
$      363
15.2 %



1Q25
($ in millions)Pre-TaxIncome
Taxes onEarnings
TaxRate
As reported (GAAP)$     1,778
$      453
25.5 %2)Specified items520
(74)


Excluding specified items$    2,298
$       379
16.5 %


1)2026 Taxes on Earnings includes the recognition of approximately $50 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Abbott Laboratories and SubsidiariesNon-GAAP Revenue ReconciliationFirst Quarter Ended March 31, 2026 and 2025($ in millions)(unaudited)



1Q26
1Q25
% Change vs. 1Q25













Non-GAAP

Abbott
ReportedImpact of
acquisition
(a)Impact of multi-
year
agreement
(b)Foreign
exchangeComparable
Revenue
Abbott
ReportedImpact of
acquisition
(a)Impact of multi-
year
agreement
(b)Comparable
Revenue
ReportedComparable
Total Company11,164706(8)(414)11,448
10,358707(24)11,041
7.83.7
U.S.4,274681(8)—4,947
4,168684(24)4,828
2.52.5
Intl6,89025—(414)6,501
6,19023—6,213
11.34.6















Total Diagnostics2,180706—(76)2,810
2,054707—2,761
6.11.8
U.S.905681——1,586
871684—1,555
3.82.0
Intl1,27525—(76)1,224
1,18323—1,206
7.81.6















Total Cancer
Diagnostics96706—(1)801
—707—707
n/a13.4
U.S.93681——774
—684—684
n/a13.2
Intl325—(1)27
—23—23
n/a19.2















Total Medical
Devices5,539—(8)(249)5,282
4,895—(24)4,871
13.2 
8.5
U.S.2,523—(8)—2,515
2,339—(24)2,315
7.98.7
Intl3,016——(249)2,767
2,556——2,556
18.08.3















Total Structural
Heart*578—(8)(29)541
531—(24)507
9.06.8
U.S.224—(8)—216
248—(24)224
(9.5)(3.6)
Intl354——(29)325
283——283
25.215.0















*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on Jan. 1, 2026. As a result, $46 million of sales in the first quarter of 2025 were moved from Structural Heart to Electrophysiology.

(a)The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

(b)Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of  a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026. Abbott Laboratories and SubsidiariesDetails of Specified ItemsFirst Quarter Ended March 31, 2026 and 2025(in millions, except per share data)(unaudited)

Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
SpecifiedsGross Margin$             2
$               7
$         422
$             1
$         432R&D(1)
(10)
—
(13)
(24)SG&A(444)
(33)
—
4
(473)Other (income) expense, net(2)
(2)
—
(3)
(7)Earnings before taxes$         449
$              52
$         422
$            13
936Taxes on Earnings (d)







(9)Net Earnings







$         945Diluted Earnings per Share







$         0.54
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.

c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Abbott Laboratories and SubsidiariesDetails of Specified ItemsFirst Quarter Ended March 31, 2025(in millions, except per share data)(unaudited)

Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
SpecifiedsGross Margin$            —
$              26
$         420
$             2
$         448R&D(1)
(16)
—
(10)
(27)SG&A(3)
(7)
—
—
(10)Other (income) expense, net(24)
—
—
(11)
(35)Earnings before taxes$           28
$              49
$         420
$           23
520Taxes on Earnings (d)







(74)Net Earnings







$         594Diluted Earnings per Share







$         0.33
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses as well as a fair value adjustment to contingent consideration related to a business acquisition.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and investment impairment charges.

d)Reflects the net tax benefit associated with the specified items. 2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 



View original content:https://www.prnewswire.com/news-releases/abbott-reports-first-quarter-2026-results-updates-guidance-to-reflect-acquisition-of-exact-sciences-302744652.htmlSOURCE Abbott

Original: Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platformMarch 30, 2026 9:00 AM
PR Newswire (US)

Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisionsAllows oncologists to order tests and view results directly in the clinical workflowABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform.Through this integration, oncology providers can now digitally order Abbott tests – individually or in combination – and receive status updates and results directly within their existing OncoEMR clinical workflow. Available Abbott tests include the Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard® tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care.The integration expands access to Abbott's Precision Oncology tests across Flatiron's national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care and where most cancer care in the U.S. takes place."We're focused on making it easier for clinicians to access the right information at the right moment of care," said Quincy Weatherspoon, VP and GM of Point of Care Solutions, Flatiron Health. "By integrating Abbott's Precision Oncology portfolio directly into OncoEMR, we're reducing friction in the workflow and helping providers move faster – from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care.""For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care," said Brian Baranick, vice president, Precision Oncology, Abbott.About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn,  Facebook, Instagram, X and YouTube.About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. 



View original content:https://www.prnewswire.com/news-releases/abbott-expands-access-to-precision-oncology-portfolio-through-integration-with-flatirons-oncoemr-platform-302728101.htmlSOURCE Abbott

Original: Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

Abbott completes acquisition of Exact SciencesMarch 23, 2026 8:50 AM
PR Newswire (US)

Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people."Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized treatments," said Robert B. Ford, chairman and chief executive officer, Abbott. "With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care."Pursuant to the terms of the merger agreement, upon completion of the acquisition, Exact Sciences became a wholly owned subsidiary of Abbott. As a result of the completion of the acquisition, March 20, 2026, was the last day of trading of Exact Sciences shares on the Nasdaq Stock Market.Strategic fitThe transaction positions Abbott to advance diagnostics that are more preventative, predictive and personalized while expanding the company's presence in one of the fastest-growing areas of healthcare as global cancer incidence continues to rise. It also adds a new growth vertical to Abbott's already high-single-digit growth expectations, establishing leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.Industry-leading offerings and pipelineAbbott now has a comprehensive suite of products and differentiated pipeline focused on the early detection of cancer and supporting personalized treatments. This includes the Cologuard® test, a market-leading noninvasive colorectal cancer screening option; Oncotype DX®, which informs personalized treatment decisions for patients with early-stage breast cancer; Oncodetect®, a tumor-informed molecular residual disease (MRD) test to help identify cancer recurrence and guide follow-up care; and Cancerguard®, a multi-cancer early detection blood test.Abbott also adds a leading pipeline of next-generation cancer screening and diagnostics designed to detect cancer even earlier, optimize treatment decisions and enable regular monitoring to help people stay healthy and better manage the disease.About AbbottAbbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn,  Facebook,  Instagram, X and YouTube.Forward-Looking StatementsThis communication contains forward-looking statements about, among other things, the acquisition of Exact Sciences by Abbott. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, the following: the ability of Abbott to successfully integrate Exact Sciences' operations; the ability of Abbott to implement its plans, forecasts and other expectations with respect to Exact Sciences' business after the completion of the transaction; and risks related to the ability of Abbott to realize the anticipated synergies and benefits of the transaction, including the possibility that the expected synergies and benefits from the transaction will not be realized or will not be realized within the expected time period.You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Abbott and Exact Sciences described in the "Risk Factors" section in each of Abbott's Annual Report on Form 10- K for the year ended December 31, 2025, and Exact Sciences' Annual Report on Form 10-K for the year ended December 31, 2025, respectively, and their respective other reports filed with the SEC. Free copies of these documents may be obtained from the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abbott undertakes no obligation, and does not intend, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments or otherwise, except as required by law.



View original content:https://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-exact-sciences-302722046.htmlSOURCE Abbott

Original: Abbott completes acquisition of Exact Sciences

With a nominal deal value of $23B (including ~$2B assumption of debt), ABT-EXAS is the largest healthcare acquisition since PFE-SGEN in Mar 2023.

Abbott acquisition of Exact Sciences set to close on March 23, 2026March 20, 2026 9:00 AM
PR Newswire (US)

Announcement follows receipt of all regulatory clearances necessary for closingTransaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional peopleABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for closing.The transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people. Together with Exact Sciences, Abbott will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages."Proactively shaping the portfolio to anticipate future medical needs while building long-term shareholder value remains at the core of our strategic framework," said Robert B. Ford, chairman and chief executive officer, Abbott. "The addition of Exact Sciences enhances Abbott's growth profile and strengthens our leadership in diagnostics. This transaction brings a powerful new platform in cancer screening and diagnostics into Abbott, advancing our mission to make care more accessible and give people more control over their health."Strategic fit
Exact Sciences is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor for recurrence.This acquisition strengthens Abbott's leadership position and capabilities in diagnostics, positioning the company to advance technologies that are more preventative, predictive and personalized. It expands Abbott's presence in one of the fastest-growing areas of healthcare as cancer incidence continues to rise worldwide. It also adds a new growth vertical to Abbott's already high-single-digit growth expectations, establishing leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.Industry-leading offerings and pipeline
Exact Sciences' product offerings include the Cologuard® test, a market-leading noninvasive colorectal cancer screening option; Oncotype DX®, which informs personalized treatment decisions for patients with early-stage breast cancer; Oncodetect®, a tumor informed molecular residual disease (MRD) test to help identify cancer recurrence and guide follow-up care; and Cancerguard®, a multi-cancer early detection blood test.Exact Sciences is also advancing a leading pipeline of next-generation cancer diagnostics designed to detect cancer even earlier, optimize treatment decisions and enable regular monitoring to help people stay healthy and better manage disease.Financial
As previously communicated, this transaction is expected to add approximately $3 billion of incremental sales in 2026, accelerate Abbott's 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per share (EPS) by approximately $0.20.About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.Forward-Looking Statements
This communication contains forward-looking statements about, among other things, the proposed acquisition of Exact Sciences by Abbott. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, the following: the possible inability of the parties to consummate the proposed transaction on a timely basis or at all; the possible inability of the parties to satisfy the conditions precedent to consummation of the proposed transaction on a timely basis or at all; the possible occurrence of any event, change or other circumstance that could give rise to the termination of the parties' definitive agreement for the proposed transaction; the ability of Abbott to successfully integrate Exact Sciences' operations, and the ability of Abbott to implement its plans, forecasts and other expectations with respect to Exact Sciences' business after the completion of the proposed transaction; risks relating to significant transaction costs associated with the proposed transaction and the possibility that the proposed transaction may be more expensive to complete than anticipated; risks related to the ability of Abbott to realize the anticipated synergies and benefits of the proposed transaction, including the possibility that the expected synergies and benefits from the proposed transaction will not be realized or will not be realized within the expected time period; potential adverse effects of the announcement or pendency of the proposed transaction; or any failure to complete the proposed transaction on the market price of Abbott's common stock, on the ability of Exact Sciences to develop and maintain relationships with its personnel (including Exact Sciences' ability to attract and retain highly qualified management and other scientific personnel) and customers, suppliers and others with whom it does business, or otherwise on Exact Sciences' or Abbott's business, financial condition, results of operations and financial performance; risks related to diversion of management's attention from Exact Sciences' ongoing business operations due to the proposed transaction; and the risk of litigation and/or regulatory actions related to the proposed transaction or Exact Sciences' business and the outcome of any such litigation or regulatory action.You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Abbott and Exact Sciences described in the "Risk Factors" section in each of Abbott's Annual Report on Form 10-K for the year ended December 31, 2025, and Exact Sciences' Annual Report on Form 10-K for the year ended December 31, 2025, respectively, and their respective other reports filed with the SEC. Free copies of these documents may be obtained from the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abbott undertakes no obligation, and does not intend, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments or otherwise, except as required by law.



View original content:https://www.prnewswire.com/news-releases/abbott-acquisition-of-exact-sciences-set-to-close-on-march-23-2026-302719347.htmlSOURCE Abbott

Original: Abbott acquisition of Exact Sciences set to close on March 23, 2026

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose managementMarch 12, 2026 3:00 AM
PR Newswire (US)

U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2Improvements were participant-led, using real-time glucose readings to guide everyday decisionsComplementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population3ABBOTT PARK, Ill., March 12, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes than those using traditional fingersticks. Improvements were achieved through participant-led self-management, guided by real-time CGM insights. Findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).About 63 million people worldwide rely on insulin to manage Type 2 diabetes4, but real-world studies show only 18%–30% of those using basal insulin are reaching their HbA1c goals.5,6 This gap  contributes to an estimated $217 billion in annual diabetes healthcare costs, indicating millions of people still need support to reach healthy glucose ranges.7 The FreeDM2 randomized controlled trial was designed to determine whether real-time continuous glucose monitoring can help people using basal insulin improve their glucose management.Conducted across 24 clinical sites in the U.K. and involving 303 participants, the study compared the effectiveness of CGM with traditional self-monitoring of blood glucose (SMBG) in people with Type 2 diabetes using basal insulin.8Significant improvements through self-management
At four months, participants using an Abbott FreeStyle Libre system for continuous glucose monitoring had a significantly greater reduction in HbA1c (0.6%; p

Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'March 11, 2026 11:00 AM
PR Newswire (US)

Abbott, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual 'Abbott Dream Team'All participants will receive sports nutrition guidance from Abbott experts and take part in on-field development sessions led by Real Madrid coachesThe 16 selected male and female 'Abbott Dream Team' members, ages 18–19, will travel to Spain on an all-expenses-paid trip to train at Real Madrid's official facilitiesLearn more and register at AbbottDreamTeam.comABBOTT PARK, Ill., March 11, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players aged 18–19 across the United States to sign up for the chance to take part in a once-in-a-lifetime development experience in Madrid. Selected participants will train with Real Madrid's world-renowned coaches at the club's facilities and enjoy unique opportunities, including attending a Real Madrid match at the Bernabéu Stadium and meeting club legends. Building on the success of last year's inaugural program, the initiative once again aims to help promising athletes strengthen their skills, knowledge and confidence on and off the pitch.







As part of the experience, Abbott health experts and Real Madrid's medical team will continue providing participants with the latest advancements in sports health and nutrition – helping them better understand their bodies, build healthier habits, and reach peak performance.Following their training in Madrid, this year's 'Abbott Dream Team' will return home to lead health and nutrition sessions with Abbott at local soccer and youth organizations, inspiring even more young players to embrace healthy habits and pursue their potential.To share invaluable perspective on the qualities needed to sustain success on the field, legendary Real Madrid player Marcelo will join this year's 'Abbott Dream Team' as a mentor."During my years at Real Madrid, I benefited from world-class nutrition and health guidance," Marcelo said. "Young players can't reach their full potential without a strong nutritional foundation, and I'm excited to work with Abbott to help the next generation build the habits and skills that fueled my career."'Abbott Dream Team' Selection Events
All selection event participants will engage in dynamic soccer development sessions led by Real Madrid coaches and receive health and nutrition education from Abbott. Attendees will receive an 'Abbott Dream Team' adidas jersey and an Abbott health toolkit. Space is limited per event, and athletes must provide proof of age. Participants will receive a confirmation notice following registration.Athletes can learn more and register at AbbottDreamTeam.com. Selection events will take place at the following locations and dates:Miami: Tuesday, May 19AutoNation Field (7620 SW 36th St, Davie, FL 33314)Washington, D.C.: Thursday, May 21Howard University (Girard St & 6th St NW, Washington, DC 20059)Houston: Wednesday, May 27South Houston High School (3820 Shaver St, South Houston, TX 77587)Kansas City: Tuesday, June 2Shawnee Mission Soccer Complex (9300 Nieman Rd, Overland Park, KS 66214)Los Angeles: Thursday, June 4California State University, Los Angeles (22 Circle Dr, Los Angeles, CA 90032)Chicago: Tuesday, June 9Intentional Sports (1841 N Laramie Ave, Chicago, IL 60639)The 'Abbott Dream Team' Madrid Experience
Following the nationwide selection events, 16 players will be picked for their teamwork, soccer skills, leadership, and growth mindset and sent on an all-expenses-paid trip to Madrid for an unforgettable experience. Members of the final roster will train with Real Madrid coaches at the club's renowned facilities, attend a match at the iconic Bernabéu Stadium, meet club legends and learn about the latest advancements in sports science from Abbott nutritionists and Real Madrid's medical team.Inspiring Health, Performance and Potential
Following their trip to Madrid, 'Abbott Dream Team' members will have the opportunity to share their knowledge and help promote the benefits of living a healthy lifestyle within their local communities by collaborating with Abbott to participate in health training events at local soccer and youth organizations."Following a successful first year, we're excited to bring back the 'Abbott Dream Team' and continue empowering young athletes through the power of nutrition and sport," said Melissa Brotz, chief marketing, communications and sustainability officer, Abbott. "Good health is critical to success on and off the pitch, and this program gives players lifelong tools they can carry with them well beyond their athletic careers. Our partnership with Real Madrid and the Dream Team program reflects that shared commitment."As the Global Health Sciences and Nutrition Partner of the Real Madrid Football Club, Abbott provides nutritional guidance for Real Madrid's first men's and women's and Academy teams through research-based dietary recommendations backed by the company's over 135-year heritage in health sciences and understanding of the needs of athletes.The 'Abbott Dream Team' program is a youth development and educational initiative and is not affiliated with player recruitment or talent scouting for Real Madrid C.F.About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn,  Facebook,  Instagram,  X and YouTube.About Real Madrid C.F.
Real Madrid C.F. is a sport entity with 124 years of history. It is the club with the most European Cups of both football (15) and basketball (11) and was awarded by FIFA as the Best Club of the twentieth century. Real Madrid has millions of fans in all corners of the world, with more than 660 million followers on social media, being the strongest football brand in the world according to Brand Finance for the fourth year in a row and also the highest earning football club in the world in the 24-25 season (Football Money League by Deloitte). More information about Real Madrid C.F. is available at www.realmadrid.com, the most visited football club website for the seventh consecutive year. 










View original content to download multimedia:https://www.prnewswire.com/news-releases/abbott-and-real-madrid-launch-nationwide-effort-to-build-the-next-abbott-dream-team-302710649.htmlSOURCE Abbott

Original: Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'

EXAS shareholders approve ABT acquisition:

https://www.businesswire.com/news/home/20260220121623/en/Exact-Sciences-Stockholders-Approve-Acquisition-by-Abbott

EXAS reports 4Q25 results:

https://www.businesswire.com/news/home/20260213963431/en/Exact-Sciences-Announces-Record-Fourth-Quarter-and-Full-Year-2025-Results

4Q25 sales were $878M, +23% YoY. No CC because of the pending acquisition by ABT.

EXAS shareholders will vote on the acquisition 2/20/26, but approval is a fait accompli.

(ABT)—EXAS Cologuard patents ruled invalid, paving the way for competition:

https://www.businesswire.com/news/home/20260206045746/en/Geneoscopy-Wins-Second-Patent-Trial-and-Appeal-Board-Decision-Invalidating-All-Challenged-Claims-of-Exact-Sciences-746-Patent

Geneoscopy, a private company, has a Cologuard-like test called ColoSense that has not yet been commercialized due to patent litigation by EXAS. With the above ruling by the PTAB, Geneoscopy can now proceed with commercialization.

I do not have an educated opinion on which test is better from a medical standpoint.

ABT, which is buying EXAS in an all-cash deal (#msg- 176971675), is down 0.2% in today’s AH session, so ABT investors evidently think Cologuard competition from ColoSense is not a big deal.

ABT independent director bought $1M of_stock_on_the_open_market_Wednesday:

https://www.sec.gov/Archives/edgar/data/1800/000090213226000003/xslF345X05/form4-02062026_010212.xml

This comes after ABT’s CEO bought $2M of stock on the open market two weeks ago (#msg-177220102).

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillationFebruary 6, 2026 8:00 AM
PR Newswire (US)

Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System's industry-leading success rate for treating AFib1New data from the FOCALFLEX CE Mark trial demonstrate the safety and efficacy of the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, to significantly reduce AFib episodes for complex cases2ABBOTT PARK, Ill., Feb. 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the company's minimally invasive therapies to treat people with atrial fibrillation (AFib). The results include 12-month findings that reinforce the long-term safety and performance of Abbott's Volt™ Pulsed Field Ablation (PFA) System, which were simultaneously published in JACC: Clinical Electrophysiology. Positive results were also presented on Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, a dual-energy, focal ablation catheter engineered to allow physicians to tailor how they deliver AFib therapy.Sustained performance of the Volt PFA System
Twelve-month data from the VOLT-AF Global IDE study found that the Volt PFA System had an industry-leading success rate (84.2%) of freedom from documented rhythm recurrence among all competitive PFA products to treat AFib episodes that come and go (Paroxysmal AFib or PAF).1Volt also delivered strong results as a treatment option for AFib episodes that last longer than seven days (Persistent AFib or PersAF), with nearly 68% of patients remaining free from an additional episode following a Volt ablation.1 Additional key findings of the single-arm trial conducted at approximately 40 centers in the United States, Europe, Canada and Australia through one year include: 1Physicians were able to use fewer therapy applications (just 4.6 applications per vein on average) than other on-market competitive PFA systems.The trial found less than 6% of patients required a repeat ablation, one of the lowest rates in the industry.Patients reported a significant improvement in quality-of-life (QoL) as measured by the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) score. This self-assessment – which evaluates changes to a person's overall symptoms and social well-being – show scores rose from 63.6 to 91.4 for PAF patients treated with Volt and from 64.2 to 91.4 for PersAF patients. The study also found zero patient complications related to either an unintended injury to the esophagus, or the breakdown of red blood cells (hemolysis), which can cause sudden kidney damage."The data for Volt confirms what I see firsthand in the procedure room with this next-generation PFA device," said Atul Verma, M.D., director of the Division of Cardiology at McGill University Health Centre and McGill University in Montreal, Canada, who treated patients as part of the VOLT-AF IDE study and presented the late-breaking data at AF Symposium. "The system's unique design enables a high degree of freedom from AFib for patients, and its impressive safety profile reduces PFA-specific complications such as hemolysis, which negatively impacts other parts of the body." The Volt PFA System secured U.S. Food and Drug Administration (FDA) approval and CE Mark in Europe last year. Commercial cases have begun in the U.S. and expansion in Europe continues. Strong data supports TactiFlex Duo Ablation Catheter, Sensor Enabled
Six-month data presented from the FOCALFLEX Global CE Mark trial confirmed the safety and effectiveness of TactiFlex Duo for treating more complex cases of AFib. The trial found a clinically meaningful success rate (81%) of freedom from documented rhythm recurrence among PAF patients. 2Patient self-reported quality-of-life scores also climbed from 64.4 to 86.4.2 This data from more than 20 centers in the European Union, United Kingdom and Australia contributed to the device's recent CE Mark approval. TactiFlex Duo is designed for focal ablation, using a dual-energy platform, which gives physicians the ability to tailor AFib therapy delivery in two ways instead of a single energy mode. Experts use the catheter to target and treat an irregular heart rhythm with either extreme heat (radiofrequency) or high-energy electrical pulses (PFA) based on a patient's individual needs and anatomy, including the most challenging cases. In addition to the CE Mark study, Abbott also completed enrollment last year for the FLEXPULSE Global IDE trial to evaluate TactiFlex Duo as an AFib therapy. Last October, the FDA granted Breakthrough Device Designation for TactiFlex Duo to treat Ventricular Tachycardia – a potentially life-threatening fast heart rate requiring immediate medical attention – using PFA."With the rising rates of AFib around the world, data from the Volt PFA and TactiFlex Duo trials help empower physicians with further confidence in using these devices to treat people with AFib – from the recently diagnosed to the most complex cases," said Christopher Piorkowski, M.D., chief medical officer of Abbott's electrophysiology business. "These studies help solidify our treatment offerings for AFib as we strive to challenge the status quo to develop even better tools that physicians can rely on to care for their patients." In addition, a late-breaking data presentation on Abbott's Amulet device will be presented on Friday, Feb. 6 between 5:30 – 7 p.m. Eastern from the VERITAS Amulet 360 Pivotal Study.For U.S. important safety information go to:
Volt™ PFA System 
https://www.cardiovascular.abbott/us/en/ep-clinical-evidence/volt-clinical-evidence.htmlTactiFlex™ Duo Ablation Catheter, Sensor Enabled™ is approved for investigational use only in the U.S.About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. Connect with us at?www.abbott.com?and on?LinkedIn,?Facebook,?Instagram,?X?and?YouTube.?1 Verma, A. (2026, February 5) 12-Month Safety and Effectiveness of a balloon-in-basket PFA system for de novo PVI to treat PAF and PsAF: Results from the VOLT-AF IDE Study [Late Breaking Presentation]. AF Symposium 2026, Boston MA, USA.
2 Deisenhofer, I. (2026, February 5) Safety and Effectiveness of the TactiFlex Duo System: 6-Month Results of the FOCALFLEX Study [Late Breaking Presentation]. AF Symposium 2026, Boston MA, USA.



View original content:https://www.prnewswire.com/news-releases/late-breaking-data-presentations-showcase-the-safety-and-efficacy-of-abbotts-ablation-catheters-to-treat-people-with-atrial-fibrillation-302680826.htmlSOURCE Abbott

Original: Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Bullish for ABT/EXAS…

https://www.businesswire.com/news/home/20260203507378/en/Exact-Sciences-Applauds-Passage-of-Legislation-Establishing-Medicare-Coverage-Pathway-for-Multi-Cancer-Early-Detection-Tests

ABT CEO bought $2M of_stock Friday on_the_open_market:

https://www.sec.gov/Archives/edgar/data/1800/000161257126000002/xslF345X05/form4-01262026_010121.xml

ABT 4Q25 Results by Business Segment
%Corp YoY Growth
Segment Sales (const currency)
Medical devices* 50% +10%
Diagnostics 21% -4%
Nutrition 17% -9%
Pharmaceuticals‡ 12% +7%62% of overall corporate sales were ex-US.

* Includes CGMs and diabetes care.
‡ Branded generics and biosimilars in emerging markets.

ABT reports 4Q25 results—issues 2026 guidance:

https://www.prnewswire.com/news-releases/abbott-reports-fourth-quarter-and-full-year-2025-results-issues-2026-financial-outlook-302668032.html

• 4Q25 sales were $11.46B, +4% YoY.

• 4Q25 non-GAAP EPS was $1.50, +12% YoY.

• New 2026 guidance for organic sales growth (which excludes FX, acquisitions, and divestitures) is 6.5-7.5%.

• New 2026 guidance for non-GAAP EPS is $5.55-5.80, +8-13% vs 2025’s $5.15.

Note: 2026 guidance does not include any contribution from the pending acquisition of EXAS (#msg-176971708).

ABT, drifting lower, reports earnings Jan 22

FDA approves ABT's pulsed-field-ablation system_for atrial fib:

https://www.prnewswire.com/news-releases/abbotts-volt-pulsed-field-ablation-system-receives-fda-approval-to-treat-patients-with-atrial-fibrillation-302647634.html • Abbott's Volt PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib).

• Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms.

• Abbott's Volt PFA System is an all-in-one product that is clinically proven to simplify the treatment of AFib that is gentler on the heart, has shorter procedure times and supports better recovery and long-term results.

ABT increases dividend for 54th (!) consecutive year:

https://www.prnewswire.com/news-releases/abbott-increases-quarterly-dividend-for-54th-consecutive-year-302640254.html

The new annualized payout of $2.52 (up from $2.36). At the current share price (~$125), the new payout equates to a dividend yield of 2.0%. Perhaps more important, ABT has increased the dividend by a cumulative 70% during the past five years.

EXAS presents data_for minimal-residual-disease—(MRD)—diagnostic for TNBC:

https://www.businesswire.com/news/home/20251211912129/en/Exact-Sciences-the-NSABP-Foundation-and-the-German-Breast-Group-Present-Results-for-the-Oncodetect-MRD-Test-in-Early-Triple-Negative-Breast-Cancer-at-SABCS

EXAS is being acquired by ABT (#msg-176971675).

Further comments on ABT-EXAS deal:

On today’s CC, ABT’s CEO acknowledged that there are no major cost synergies in the EXAS deal, which is surprisingly honest. (Almost all M&A deals come with optimistic projections for cost synergies.) The reason ABT can say that EXAS will be accretive to EPS in 2028 is the operating leverage that comes from an increased volume of tests.

Moreover, ABT has a conservative balance sheet, so more financial leverage can help boost EPS without lowering ABT’s credit rating. The hurdle to boost EPS is pretty low with the interest rates ABT can expect to pay on newly issued debt to fund the acquisition.

Factoid: ABT-EXAS is the biggest healthcare deal since PFE-SGEN.

ABT CEO response to CC question on competition to Cologuard from blood tests was weak and incomplete, IMO. He should have said that, scientifically, it's all but impossible for a blood test to match the sensitivity/specificity of a stool-based test for detecting colorectal cancer.

ABT/EXAS—But it will not be accretive to EPS immediately or in the near future. Slide 12 from today’s CC slide set says the deal will be accretive to EPS in 2028.

https://www.abbott.com/content/dam/corp/abbott/en-us/hub-new/Presentation-Acquisition-of-Exact-Sciences.pdf

ABT-EXAS CC slides:

https://www.abbott.com/content/dam/corp/abbott/en-us/hub-new/Presentation-Acquisition-of-Exact-Sciences.pdf

ABT acquires EXAS for $105/sh cash—a 51% premium to Tuesday’s closing price (before Bloomberg leaked the deal on Wednesday):

https://www.prnewswire.com/news-releases/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-precision-oncology-diagnostics-segments-302621643.html
• Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.

• Acquisition will be immediately accretive to Abbott's revenue growth and gross margin. But it will not be accretive to EPS immediately or in the near future.

The nominal deal value (including assumed debt) is $23B.

Reason for ABT selloff today: #msg-176968355.

ABT 3Q25 Results by Business Segment
%Corp YoY Growth
Segment Sales (const currency)
Medical devices* 48% +13%
Diagnostics 20% -8%
Nutrition 19% +4%
Pharmaceuticals‡ 13% +7%62% of overall corporate sales were ex-US.

* Includes CGMs and diabetes care.
‡ Branded generics and biosimilars in emerging markets.

ABT reports 3Q25 results—tightens_2025_EPS_guidance at lower and upper bounds:

https://abbott.mediaroom.com/2025-10-15-Abbott-Reports-Third-Quarter-2025-Results-and-Reaffirms-Full-Year-Guidance

3Q25 sales were $11.37B, +6% YoY in constant currency.

3Q25 non-GAAP EPS was $1.30, +7% vs $1.21 in 3Q24.

3Q25 sales of continuous glucose monitors were $2.0B (!), +20% YoY in constant currency.

--
2025 guidance for non-GAAP EPS (which excludes FX and restructuring costs) is now $5.12-5.18, narrowed from the prior guidance $5.10-5.20. The new 2025 non-GAAP EPS guidance is +10-11% relative to 2024’s actual $4.67.

2025 guidance for organic sales growth remains 6.0-7.0%. (This range was lowered from 7.5-8.5% three months ago due to: 1) lower sales of COVID diagnostics; 2) lower sales of core-lab diagnostics systems in China; and 3) reduced US funding for HIV drugs in emerging markets.)

ABT continues to expects an approximately $200M headwind from tariffs in 2025.

ABT expects a $200M headwind from tariffs in 2025. The reason this number is not bigger is that 62% of ABT’s sales are ex-us (#msg-176777975) and ABT does most of its manufacturing locally.

ABT 2Q25 Results by Business Segment
%Corp YoY Growth
Segment Sales (const currency)
Medical devices* 48% +12%
Diagnostics 20% -1%
Nutrition 20% +3%
Pharmaceuticals‡ 12% +8%62% of overall corporate sales were ex-US.

* Includes CGMs and diabetes care.
‡ Branded generics and biosimilars in emerging markets.

3-minute interview with ABT CEO:

ABT 3Q15 earnings release 10/15/25:

https://www.prnewswire.com/news-releases/abbott-hosts-conference-call-for-third-quarter-earnings-302565369.html

Yesterday's selloff was an overreaction, according to Jefferies:

https://finance.yahoo.com/news/abbott-upgraded-post-earnings-selloff-130319844.html Jefferies upgraded Abbott Laboratories to Buy from Hold, calling the market reaction to the company’s latest results “too punitive” and arguing that near-term headwinds in diagnostics are likely to ease. I fully agree.

Non-issue, IMO. People taking GLP-1 meds and other weight-loss drugs make more use of CGMs than people who aren't taking these drugs.

How do we feel about the GLP-1 affect on diabetes numbers, and how that may impact glucose monitoring sales?

Oversold. The health industry is getting destroyed by cuts from the big beautiful bill. Good fire sales to be had. There may be a little bump up this morning, followed by another drop, so will watch for a better entry point.

Was the price movement justified?